Core Viewpoint - The A-share pharmaceutical sector in 2025 exhibits structural differentiation, with innovative drugs and CXO sectors thriving due to overseas demand and business development, while traditional Chinese medicine, medical devices, and pharmaceutical commerce face performance pressures [3][20]. Summary by Category Overall Market Performance - The A-share pharmaceutical and biotechnology sector saw an overall increase of 25.64% from January 1 to December 30, 2025, despite a slight decline in revenue and a stabilization in profits, with total revenue of 18,544.52 billion yuan, down 1.42% year-on-year, and net profit of 1,407.32 billion yuan, down 1.65% year-on-year [4][21]. Innovative Drug Sector - The innovative drug sector was a standout performer in 2025, with the chemical pharmaceutical segment rising by 32.58% and the medical services segment by 32.91% [4][21]. - Companies like BeiGene (百济神州) reported significant growth, achieving revenue of 27.595 billion yuan, a 44.2% increase year-on-year, surpassing the total revenue of 27.21 billion yuan for 2024 [4][22]. Business Development (BD) Trends - The business development landscape for innovative drug companies is evolving, with significant partnerships such as the 11.4 billion USD deal between Innovent Biologics and Takeda, and a 12.5 billion USD collaboration between Hengrui Medicine and GlaxoSmithKline [5][22][24]. - The total value of business development transactions reached approximately 94.158 billion USD in the first three quarters of 2025, significantly exceeding the total for 2024 [25]. CXO Sector Performance - The CXO sector, driven by the demand for innovative drug research, achieved a 32.91% increase in 2025, with total revenue of 1,365.72 billion yuan, up 3.63% year-on-year, and net profit of 209.12 billion yuan, up 36.47% year-on-year [10][27]. - Leading companies like WuXi AppTec (药明康德) and Kanglong Chemical (康龙化成) returned to growth, with WuXi AppTec reporting a revenue increase of 18.61% and net profit growth of 84.84% [28][31]. Traditional Chinese Medicine and Medical Devices - The traditional Chinese medicine sector experienced a modest increase of 6.75% in 2025, with total revenue of 2,590.69 billion yuan, down 4.33% year-on-year, and net profit of 294.99 billion yuan, down 1.53% year-on-year [36]. - The medical device sector reported a revenue of 1,792.10 billion yuan, down 2.24% year-on-year, with notable performance differences among sub-sectors, where companies like Mindray Medical (迈瑞医疗) showed strong overseas revenue growth [33][34].

Group 1: Core Insights - The report maintains a strong market rating for the pharmaceutical industry, indicating a clear upward trend driven by recovering demand and improved performance in the CXO sector [1][2] - The CXO sector has shown significant stock price increases, with some companies experiencing nearly 100% growth since the beginning of 2025, driven by the innovative drug market and a recovery in orders [3][6] Group 2: CXO Sector Analysis - The CXO sector's overall revenue increased by 11.8% year-on-year in the first three quarters of 2025, with a notable profit increase of 58.1% [13] - External demand for CXO services has rebounded, with significant order growth from leading CDMO companies, indicating a clear recovery trend [22][31] - Internal demand for CXO services has lagged behind external demand, but there are signs of strong growth in domestic innovative drug projects and increased investment in the domestic market [3][22] Group 3: Life Sciences Upstream - The life sciences upstream sector has seen a 37.7% increase in stock prices year-to-date, outperforming the pharmaceutical and biotechnology index by 18% [3] - Revenue for the upstream sector increased by 8.8% year-on-year in the first three quarters of 2025, with net profit rising by 27.7% [3] Group 4: Investment Recommendations - The report suggests a strategic investment focus on companies such as WuXi AppTec, WuXi Biologics, and Tigermed, while also highlighting more flexible investment options like Zhaoyan New Drug and Nossan [3]

Group 1 - The Hong Kong stock market saw a decline in CRO (Contract Research Organization) concept stocks, with notable drops in several companies [1] - Zhaoyan New Drug fell over 7%, while Kanglong Chemical and King’s Ray dropped over 4% [1] - Kylin and Weiya Bio experienced declines of over 2% [1]

Summary of Key Points from the Equity Research Report Industry Overview - The report focuses on the **China CXO (Contract Research Organization) sector**, highlighting growth prospects and investment opportunities for 2026 and beyond [2][3]. Core Insights and Arguments - The **2026 National Defense Authorization Act (NDAA)** was signed, which includes a revised Biosecure provision that reduces geopolitical risks and ensures continuity of US orders for Chinese companies [3][4]. - The **Federal Reserve's anticipated rate cuts** (two to three 25 basis points cuts in 2026) are expected to revive biotech financing, enhancing demand for CXO services [3][4]. - The **Chinese CXO competitive advantage** is strengthening due to economies of scale, AI-driven efficiencies, and advancements in niche technologies like antibody drug conjugates (ADCs) and peptides [3][4]. - The report forecasts **11-39% net profit growth** for major players in the CXO industry by 2026, supported by low-teen order growth [4][5]. Valuation and Investment Recommendations - Current valuations are considered attractive, with an average **30x 2026e PE** and **1.1x 2026e PEG** [4]. - Investment themes include: 1. Launch of the **1260H list** in January 2026 for risk mitigation. 2. Full-industry-chain leaders like **Wuxi Apptec** and **Wuxi Biologics** with global scalability. 3. High-growth specialists like **Wuxi XDC** focusing on niche markets and overseas expansion. 4. Domestic recovery names like **Pharmaron** offering stable profitability [5][9]. Company-Specific Updates Wuxi Apptec - Target price maintained at **RMB137.00** for A-shares and **HKD133.90** for H-shares, implying **51.2% and 30.9% upside** respectively [6][33]. Wuxi Biologics - Target price remains at **HKD45.00**, with a **37.5% upside** from current levels. Revenue estimates for 2025-27 have been slightly decreased by 1-3% due to competitive pricing pressures [20][22][33]. Wuxi XDC - Target price increased to **HKD90.50** from **HKD90.00**, reflecting a **33.2% upside**. Revenue estimates for 2025-27 have been reduced by approximately 3% each due to lower-than-expected capacity ramp-up [26][28][33]. Pharmaron - Target price set at **RMB41.00** for A-shares and **HKD30.80** for H-shares, indicating **41% and 44% upside** respectively. The valuation is based on a DCF model with unchanged assumptions [33]. Risks to Monitor - Potential expansion of US biotech restrictions and geopolitical tensions could impact the sector [4][5]. - Risks include capacity surplus from rapid industry expansion, slower-than-expected recovery in biotech financing, and increased regulatory compliance costs [4][5][25][33]. Additional Important Insights - The report emphasizes the importance of monitoring the **1260H list** updates and the potential impact of US tariffs on the CXO sector [10][25]. - The **global healthcare funding** has shown signs of recovery, with a **18% year-on-year growth** in 1H25, which may take time to reflect in CXO backlogs [12][22]. This comprehensive analysis provides a detailed overview of the current state and future outlook of the China CXO sector, highlighting key players, investment opportunities, and associated risks.

Summary of Conference Call Records Industry Overview - The pharmaceutical sector is experiencing structural heat, with certain stocks entering a value range, indicating potential for rebound. The focus for 2026 includes three main narratives: innovation going global, turnaround from difficulties, and impulse-driven growth, particularly in BD 2.0, small nucleic acids, and supply chains [1][2] Key Insights and Arguments - The CRO (Contract Research Organization) industry has seen short-term risks largely mitigated, with limited impact from the U.S. NBA 2026 Act. The CRO supply chain is expected to experience a resonance of internal and external demand starting in 2024, leading to a strong fundamental outlook by 2026 [1][4] - In the clinical CRO space, companies like Tigermed are showing significant order growth, with EPS expected to experience nonlinear growth, enhancing stock price elasticity. The peptide CDMO (Contract Development and Manufacturing Organization) sector is also expected to grow at least 25% by 2026, with companies like WuXi AppTec and Notch being noteworthy [1][4][5] - CDMO companies are driven by large product orders, with ADC (Antibody-Drug Conjugates) and small nucleic acids identified as key future growth areas. ADC commercialization is entering a boom phase, benefiting companies like WuXi Biologics, Haoyuan, and Kelaiying [1][6] Additional Important Content - The Ant Group's healthcare model, Antifufu, aims to become a leading health service consultation platform, targeting 500 million registered users and over 100 million monthly active users by the end of 2026. The healthcare team has been elevated to a business group, aiming for revenue exceeding 100 billion [2][7] - Antifufu's technology is based on the "Bailing" general model, integrating Deepseek and Tongyi Qianwen technologies, utilizing proprietary medical data from various sources, including 700 million medical insurance users and 40,000 doctors from acquired platforms [2][8] - User retention strategies for Antifufu include health goal setting and integration with wearable devices, aiming for increased interaction frequency [2][9] - The commercialization strategy includes paid consultations, medication purchases, and health membership services, with B2B collaborations with insurance companies for disease-specific insurance products [2][10] - Collaboration with Alibaba Health leverages a vast user base and medical data, enhancing competitive advantages in the healthcare sector [2][11] - The AI-powered "Famous Doctor Avatar" service is currently in a testing phase, with plans for monetization contingent on achieving high diagnostic accuracy [2][12]

Group 1 - The company Kanglong Chemical announced that its actual controller, Lou Xiaoqiang, pledged 5,220,000 shares, accounting for 8.62% of his holdings [1] - The company's concerted action parties, Longtai Kang and Beihai Duotai, collectively released the pledge of 6,930,000 shares and extended the pledge of 15,970,000 shares until December 25, 2026 [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年12月24日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；職工 代表董事李承宗先生；非執行董事李家慶先生及萬璇女士；獨立非執行董事李麗 華女士、曾勁峰教授及余堅先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-071 关于公司实际控 ...

Group 1 - The core point of the news is that Kanglong Chemical conducted a block trade on December 24, with a transaction volume of 1.38 million shares and a transaction amount of 39.5363 million yuan, at a price of 28.65 yuan, which is a 0.90% discount compared to the closing price of the day [2][3] - In the last three months, Kanglong Chemical has recorded a total of 9 block trades, with a cumulative transaction amount of 266 million yuan [2] - The closing price of Kanglong Chemical on the day of the report was 28.91 yuan, reflecting a 0.35% increase, with a daily turnover rate of 0.95% and a total transaction amount of 391 million yuan, alongside a net inflow of main funds amounting to 6.1722 million yuan [2][3] Group 2 - The latest margin financing balance for Kanglong Chemical is 1.111 billion yuan, which has increased by 14.5693 million yuan over the past five days, representing a growth rate of 1.33% [3] - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, with a registered capital of 1.778195525 billion yuan [3]

证券代码：300759 证券简称：康龙化成 公告编号：2025-072 2、股东减持股份情况 股东名称 减持方式 减持期间 减持均价（元 /股） 减持价格区 间（元/股） 减持股数 （股） 减持比例 （%） 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东减持计划实施完成的公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）及其一致行 动人深圳市信中龙成投资合伙企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 11 月 14 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东 减持股份的预披露公告》（公告编号：2025-064）。公司持股 5%以上股东深圳 市信中康成投资合伙企业（有限合伙）（以下简称"信中康成"）计划自该公告 披露之日起 15 个交易日后（2025 年 12 月 8 日）的 3 个月内以集中竞价、大宗 交易等深圳证券交易所认可的合法方式减持公司股 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-071 康龙化成（北京）新药技术股份有限公司 2、本次股份解除质押基本情况 | 股 东 | 是否为控 股股东或 | 质押数量 | 占其所 | 占公司 | 是否 | 是否 为补 | 质押起 | 原质押 | 延期购 | 质权 | 质押用 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名 称 | 第一大股 东及其一 | （股） | 持股份 比例 | 总股本 比例 | 为限 售股 | 充质 押 | 始日 | 到期日 | 回后质 押到期 日 | 人 | 途 | | | 致行动人 | | | | | | | | | | | | 龙 泰 | 实际控制 人的一致 | 4,580,000 | 11.41% | 0.26% | 否 | 否 | 年 2024 月 12 25 日 | 年 2025 月 12 25 日 | 2026 年 12 月 25 日 | 中信 证券 股份 | 置换存 量金融 机构融 | | 康 | 行动人 | 8,200,000 | 20. ...